[Monoclonal antitumor antibodies--its application to diagnosis and treatment of tumors].
The two types of monoclonal anti-melanoma antibodies (M562 and M2590) were obtained by the fusion of P3U1 myeloma cells and spleen cells of C57BL/6 mice hyperimmunized with mitomycin C-treated syngeneic B16 melanoma cells. The M2590 antibody recognized the cross-species melanoma determinant commonly shared among at least mouse, hamster and human melanoma cells, while the M562 antibody reacted with the mouse (B16) specific melanoma antigenic determinant. The M2590 antibody reacted specifically in radioimmunoassay with NP40 tumor cell extracts obtained from melanoma patients but not from other tumor patients. Thus this antibody would provide a powerful tool for immunodiagnostic evaluation of patients with malignant melanoma. Moreover, these antibodies were found to suppress the growth of melanoma cells in vivo.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000032:analysis*; D006801:Humans; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology; D011863:Radioimmunoassay
D000911:Antibodies, Monoclonal